3.24

1.52% -0.05

After Hours: 3.06 -0.18 -5.56%

Qualigen Therapeutics Inc (QLGN)

Overview News Price History Financials Discussions Forecast Stock Split

Qualigen Therapeutics Inc stock is traded at $3.24, with a volume of 1,244. It is down -1.52% in the last 24 hours and up +4.52% over the past month. Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Previous Close:

$3.29

Open:

$3.23

24h Volume:

1,244

Relative Volume:

0.02

Market Cap:

$2.28M

Revenue:

$4.79M

Net Income/Loss:

$-13.42M

P/E Ratio:

-1.218

EPS:

-2.66

Net Cash Flow:

$-10.30M

1W Performance:

+6.23%

1M Performance:

+4.52%

6M Performance:

-59.55%

1Y Performance:

-78.21%

1-Day Range:

$3.18

$3.24

1-Week Range:

$2.85

$3.44

52-Week Range:

$2.85

$29.43

Qualigen Therapeutics Inc Stock (QLGN) Company Profile

Name

Qualigen Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(760) 918-9165

Address

2042 CORTE DEL NOGAL, CALIFORNIA

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

QLGN's Discussions on Twitter

Compare QLGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
QLGN Qualigen Therapeutics Inc	3.24	2.28M	4.79M	-13.42M	-10.30M	-2.66
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Qualigen Therapeutics Inc Stock (QLGN) Latest News

Apr 10, 2025

QLGN stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa

Apr 10, 2025

QLGN stock touches 52-week low at $2.9 amid market challenges - Investing.com India

Apr 10, 2025

Apr 09, 2025

Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 1.2% – Should You Sell? - Defense World

Apr 09, 2025

Apr 01, 2025

Qualigen Therapeutics Delays Yearly Financial Report - TipRanks

Apr 01, 2025

Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire

Apr 01, 2025

Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com

Apr 01, 2025

Qualigen Therapeutics to acquire Marizyme in strategic move By Investing.com - Investing.com South Africa

Apr 01, 2025

Medical Breakthrough: Qualigen's Strategic Move to Transform $10B Heart Surgery Market - Stock Titan

Apr 01, 2025

Feb 16, 2025

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 49.4% in January - Defense World

Feb 16, 2025

Jan 28, 2025

This Breakthrough Could Cut Antibiotic Testing Time in HalfQualigen's Strategic Investment - StockTitan

Jan 28, 2025

Jan 17, 2025

Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve

Jan 17, 2025

Jan 10, 2025

Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World

Jan 10, 2025

Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World

Jan 10, 2025

Dec 19, 2024

Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World

Dec 19, 2024

Dec 10, 2024

SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow

Dec 10, 2024

Dec 06, 2024

Qualigen Therapeutics regains compliance with Nasdaq's listing requirements - MSN

Dec 06, 2024

Dec 05, 2024

Qualigen Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK

Dec 05, 2024

Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire

Dec 05, 2024

Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement - Yahoo Finance

Dec 05, 2024

Nov 25, 2024

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - The Manila Times

Nov 25, 2024

Univest Securities, LLC Announces Successful Closing of - GlobeNewswire

Nov 25, 2024

Nov 22, 2024

Qualigen Therapeutics, Inc. announced that it expects to receive $5.1 million in funding - Marketscreener.com

Nov 22, 2024

Nov 19, 2024

Qualigen Therapeutics secures $4.5 million in funding By Investing.com - Investing.com South Africa

Nov 19, 2024

Qualigen Therapeutics secures $4.5 million in funding - Investing.com India

Nov 19, 2024

Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - The Manila Times

Nov 19, 2024

Nov 18, 2024

Qualigen Therapeutics (NASDAQ:QLGN) versus Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Review - Defense World

Nov 18, 2024

Nov 15, 2024